Page 130 - MI-1-1

Microbes & Immunity Re-emergence of M. pneumoniae in the post-COVID-19 era

study. PLoS Med. 2013;10(5):e1001444. doi: 10.1177/03000605211016376
doi: 10.1371/journal.pmed.1001444 21. Loconsole D, De Robertis AL, Sallustio A, et al. Update
on the epidemiology of macrolide-resistant Mycoplasma
18. Lokida D, Farida H, Triasih R, et al. Epidemiology of
community-acquired pneumonia among hospitalised pneumoniae in Europe: A systematic review. Infect Dis
children in Indonesia: A multicentre, prospective study. Rep. 2021;13(3):811-820.
BMJ Open. 2022;12(6):e057957. doi: 10.3390/idr13030073
doi: 10.1136/bmjopen-2021-057957 22. Jiang TT, Sun L, Wang TY, et al. The clinical significance of
macrolide resistance in pediatric Mycoplasma pneumoniae
19. Yun KW. Community-acquired pneumonia in children:
An updated perspectives on its etiology, diagnosis, and infection during COVID-19 pandemic. Front Cell Infect
treatment. Clin Exp Pediatr. 2024;67(2):80-89. Microbiol. 2023;13:1181402.
doi: 10.3389/fcimb.2023.1181402
doi: 10.3345/cep.2022.01452
23. Lin L, Zhang R, Zhang Z, et al. Clinical value of metagenomics
20. Xu C, Deng H, Zhang J, et al. Mutations in domain V
of Mycoplasma pneumoniae 23S rRNA and next-generation sequencing in antibiotic resistance of a patient
clinical characteristics of pediatric M. pneumoniae with severe refractory Mycoplasma pneumoniae pneumonia:
pneumonia in Nanjing, China. J Int Med Res. 2021; A case report. Infect Drug Resist. 2023;16:4593-4597.
49(6):3000605211016376. doi: 10.2147/IDR.S419873

Volume 1 Issue 1 (2024) 124 doi: 10.36922/mi.3599